Drug Profile
A 300
Alternative Names: A-300Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator AfaSci
- Class Antidementias; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alzheimer's disease
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 22 Jul 2016 A 300 is available for licensing as of 22 Jul 2016. http://www.afasci.com/
- 22 Jul 2016 Preclinical trials in Alzheimer's disease in USA (unspecified route)